SCHEMBL2523375

SCHEMBL2523375

Oc1ccc(CN(Cc2cccs2)Cc2ccc(O)c3ncccc23)c2cccnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.55
L3MBTL1 Q9Y468 5/20 0.55
HTT P42858 3/20 0.55
LMNA P02545 3/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
GAA P10253 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MAOA P21397 1/20 0.51
ACHE P22303 1/20 0.51
MAOB P27338 1/20 0.51
BACE1 P56817 1/20 0.51
ALOX12 P18054 3/20 0.49
PAX8 Q06710 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
BRD4 O60885 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TP53 P04637 2/20 0.46
MAPT P10636 2/20 0.46
ALOX15 P16050 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2519345 0.86 KDM4E (0.72) KDM4EL3MBTL1HTTLMNANPC1
SCHEMBL2770667 0.82 KDM4E (0.55) KDM4EL3MBTL1HTTLMNANPC1
SCHEMBL2524247 0.80 KMT2A (0.44) KDM4EL3MBTL1HTTRAB9ASMN1; SMN2
SCHEMBL2516006 0.79 PAX8 (0.69) KDM4EL3MBTL1HTTLMNANPC1
SCHEMBL2519523 0.79 PAX8 (0.69) KDM4EL3MBTL1HTTLMNANPC1
SCHEMBL5594514 0.78 KDM4E (0.64) KDM4EL3MBTL1HTTLMNANPC1
SCHEMBL2523380 0.76 KDM4E (0.60) KDM4EL3MBTL1HTTLMNANPC1
SCHEMBL2519988 0.75 KMT2A (0.60) KDM4EL3MBTL1HTTLMNANPC1
SCHEMBL2519855 0.75 BRD4 (0.62) KDM4EL3MBTL1HTTLMNANPC1
SCHEMBL2516487 0.75 PAX8 (0.53) KDM4EL3MBTL1HTTLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382193-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE Biopharmed (FR) 2011-11-02 EP claimed
US-20110251238-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE BIOPHARMED (FR) 2011-10-13 US claimed
WO-2010073235-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE BIOPHARMED (FR) 2010-07-01 WO claimed
EP-2382193-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE Biopharmed (FR) 2011-11-02 EP disclosed
US-20110251238-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE BIOPHARMED (FR) 2011-10-13 US disclosed
WO-2010073235-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE BIOPHARMED (FR) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251238-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE PPARA, PPARG, PPARD KDM4E 4239/4885L3MBTL1 4433/4885HTT 2008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.